BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karantanos T, Jones RJ. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. In: Birbrair A, editor. Stem Cells Heterogeneity in Cancer. Cham: Springer International Publishing; 2019. pp. 153-69. [DOI: 10.1007/978-3-030-14366-4_9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Karantanou C, Minciacchi VR, Karantanos T. Extracellular Vesicles in Myeloid Neoplasms. Int J Mol Sci 2022;23:8827. [PMID: 35955960 DOI: 10.3390/ijms23158827] [Reference Citation Analysis]
2 Dancik GM, Voutsas IF, Vlahopoulos S. Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia. Mol Biol Rep 2022. [PMID: 35028852 DOI: 10.1007/s11033-021-07073-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Y, Liu D, Li F, Zhao Z, Liu X, Gao D, Zhang Y, Li H. Identification of biomarkers for acute leukemia via machine learning-based stemness index. Gene 2021;804:145903. [PMID: 34411647 DOI: 10.1016/j.gene.2021.145903] [Reference Citation Analysis]
4 Kocibalova Z, Guzyova M, Borovska I, Messingerova L, Copakova L, Sulova Z, Breier A. Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway. Cancers (Basel) 2021;13:3629. [PMID: 34298843 DOI: 10.3390/cancers13143629] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Niu LT, Wang YQ, Wong CCL, Gao SX, Mo XD, Huang XJ. Targeting IFN-γ-inducible lysosomal thiol reductase overcomes chemoresistance in AML through regulating the ROS-mediated mitochondrial damage. Transl Oncol 2021;14:101159. [PMID: 34252711 DOI: 10.1016/j.tranon.2021.101159] [Reference Citation Analysis]
6 Yanagisawa B, Perkins B, Karantanos T, Levis M, Ghiaur G, Smith BD, Jones RJ. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leuk Res 2020;99:106477. [PMID: 33220589 DOI: 10.1016/j.leukres.2020.106477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Yang W, Xie J, Hou R, Chen X, Xu Z, Tan Y, Ren F, Zhang Y, Xu J, Chang J, Wang H. Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression. Leuk Res 2020;92:106351. [PMID: 32224355 DOI: 10.1016/j.leukres.2020.106351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang M, Wu H, Duan M, Yang Y, Wang G, Che F, Liu B, He W, Li Q, Zhang L. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells. Life Sci 2019;232:116663. [PMID: 31323275 DOI: 10.1016/j.lfs.2019.116663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Liu Y, Gao X, Tian X. High expression of long intergenic non-coding RNA LINC00662 contributes to malignant growth of acute myeloid leukemia cells by upregulating ROCK1 via sponging microRNA-340-5p. Eur J Pharmacol 2019;859:172535. [PMID: 31306637 DOI: 10.1016/j.ejphar.2019.172535] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]